文献速递脑血管病

Glenzocimab联合静脉溶栓治疗急性缺血性卒中:ACTISAVE随机双盲研究

Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study.
PubMed 文献 · Stroke · 2026-03-16

ACTISAVE为国际多中心随机双盲安慰剂对照2/3期研究,纳入溶栓(±机械取栓)的急性缺血性卒中患者438例,按1:1给予Glenzocimab 1000 mg IV或安慰剂。90天mRS 4-6比例为21.6%对15.3%(OR 1.51,95%CI 0.90-2.54,P=0.120),未达统计学差异,次要结局亦无显著差异,未发现重大安全性信号。

要点

  • Glenzocimab 1000 mg IV未改善90天mRS 4-6比例(21.6%对15.3%,P=0.120)。
  • 任何颅内出血发生率两组接近(28.6%对29.9%),未见重大安全性信号。
  • 该药加入溶栓(±取栓)未能确认此前ACTIMIS提示的获益。

核心结论

  • ACTISAVE未能证实Glenzocimab对接受溶栓治疗的急性缺血性卒中患者mRS有获益作用。

研究设计与样本

  • 国际、随机、双盲、安慰剂对照2/3期研究,在10个国家54个卒中中心开展。
  • 随机纳入438例,1:1分为Glenzocimab 1000 mg-IV组或安慰剂组,421例接受治疗并纳入主要分析集。
  • 入组为症状发作4.5小时内接受溶栓、伴或不伴机械取栓的卒中患者;中位年龄73(63-80)岁,43%为女性。

主要发现

  • 90天不良结局(mRS 4-6对0-3)发生率Glenzocimab组21.6%、安慰剂组15.3%(OR 1.51,95%CI 0.90-2.54,P=0.120)。
  • 次要结局(含mRS 0-2、死亡、mRS移位、NIHSS、生活质量)均未观察到统计学显著差异。
  • 任何颅内出血分别见于Glenzocimab组60例(28.6%)和安慰剂组63例(29.9%),无重大安全性信号。

关键数值与推荐

  • Glenzocimab剂量为1000 mg静脉给药,在溶栓开始后中位1.2(IQR 0.8-1.6)小时开始输注。
  • 溶栓在症状发作后中位2.3小时进行,36%患者随后接受机械取栓;溶栓前NIHSS中位9(6-15)。

临床怎么用

  • 结果不支持在溶栓(±取栓)基础上常规加用Glenzocimab,仍需等待进一步研究明确其价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glenzocimab, a platelet glycoprotein VI antagonist, is a novel agent that inhibits platelet activation and aggregation. Its safety was demonstrated in the ACTIMIS trial (Acute Ischemic Stroke Interventional Study; URL: https://www.clinicaltrials.gov; Unique identifier: NCT03803007) for patients with stroke receiving thrombolysis, with or without mechanical thrombectomy, and results suggested a reduction in intracranial hemorrhages and mortality. The ACTISAVE trial was designed as a confirmatory study to evaluate the efficacy and safety of glenzocimab in acute ischemic stroke. METHODS: ACTISAVE (Acute Ischemic Stroke Study Evaluating Glenzocimab Used as Add-On Therapy Versus Placebo) was an international, randomized, double-blind, placebo-controlled phase 2/3 study in patients with stroke, treated by thrombolysis within 4.5 hours of symptoms onset with or without mechanical thrombectomy. The study was conducted at 54 primary and comprehensive stroke centers located in 10 countries. Patients were randomized 1:1 to glenzocimab (1000 mg-IV) or placebo. The primary outcome was the modified Rankin Scale (mRS) score of 4 to 6 at day 90. Key secondary outcome was the mRS score of 0 to 2 at day 90. Mortality, mRS shift, National Institutes of Health Stroke Scale score, quality of life, and safety outcomes were assessed. RESULTS: Between September 2021 and October 2023, 438 patients were randomized, 421 treated, and included as randomized in the primary analysis set. Median age was 73 (63-80) years, and 43% were female. Thrombolysis was performed 2.3 hours (median) after symptom onset and followed by mechanical thrombectomy in 36% of patients. The assigned treatment began a median of 1.2 (interquartile range, 0.8-1.6) hours after thrombolysis initiation. Prethrombolysis National Institutes of Health Stroke Scale score median was 9 (6-15). At day 90, there was no statistically significant difference in the primary outcome between the treatment groups: the incidence of poor outcome (mRS score 4-6 versus 0-3) was 21.6% in the glenzocimab group compared with 15.3% placebo group (odds ratio, 1.51 [95% CI, 0.90-2.54]; P=0.120). No statistically significant difference in secondary outcomes was observed. There were no major safety signals with any intracerebral hemorrhage occurring respectively in 60 (28.6%) and 63 (29.9%) patients in glenzocimab and placebo arms. CONCLUSIONS: ACTISAVE failed to confirm a beneficial effect of glenzocimab on mRS in patients with acute ischemic stroke treated by thrombolysis. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05070260.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Köhrmann M, Berrouschot J, Serena J, et al. Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study. Stroke. 2026. PMID: 42044230. doi:10.1161/STROKEAHA.125.052935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。